YIH
ACAD icon

Y-Intercept (HK)’s Acadia Pharmaceuticals ACAD Stock Holding History

Y-Intercept (HK)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,664
Closed -$571K – 1656
2026
Q1 		$571K Buy
+25,664
New +$613K 0.01% 1229
2025
Q4 		– Sell
-111,273
Closed -$2.37M – 1486
2025
Q3 		$2.37M Buy
+111,273
New +$2.63M 0.06% 512
2025
Q2 		– Sell
-14,527
Closed -$241K – 1593
2025
Q1 		$241K Sell
14,527
-18,378
-56% -$334K 0.02% 983
2024
Q4 		$604K Sell
32,905
-17,639
-35% -$285K 0.04% 638
2024
Q3 		$777K Sell
50,544
-39,245
-44% -$655K 0.05% 554
2024
Q2 		$1.46M Sell
89,789
-51,647
-37% -$834K 0.08% 347
2024
Q1 		$2.62M Buy
+141,436
New +$3.5M 0.2% 115
2023
Q4 		– Sell
-68,887
Closed -$1.44M – 1178
2023
Q3 		$1.44M Buy
68,887
+48,928
+245% +$1.33M 0.14% 216
2023
Q2 		$478K Sell
19,959
-8,190
-29% -$182K 0.05% 578
2023
Q1 		$530K Buy
28,149
+4,286
+18% +$81.6K 0.06% 497
2022
Q4 		$380K Sell
23,863
-5,278
-18% -$82.5K 0.06% 546
2022
Q3 		$477K Buy
29,141
+15,071
+107% +$244K 0.05% 556
2022
Q2 		$198K Buy
14,070
+4,169
+42% +$77.8K 0.03% 686
2022
Q1 		$240K Sell
9,901
-98
-1% -$2.37K 0.05% 538
2021
Q4 		$233K Buy
+9,999
New +$201K 0.06% 470

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Y-Intercept (HK)'s ACAD Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 25,664 shares — an estimated $571K sold.

Y-Intercept (HK) first reported a position in ACAD in Q4 2021 and held it in 15 quarters. The position peaked at $2.62M in Q1 2024. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Y-Intercept (HK) reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 25,664 Acadia Pharmaceuticals shares in Q2 2026, an estimated $571K.
  • Y-Intercept (HK) first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 15 quarters.
  • Y-Intercept (HK)'s Acadia Pharmaceuticals position peaked at $2.62M in Q1 2024.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.